PTEN Is Activated by the Addition of Cetuximab to Paclitaxel in Oral Squamous Cell Carcinoma

被引：4
作者：
Kii, Tomoyuki [1 ]
Sakuma, Kaname [2 ]
Tanaka, Akira [1 ,2 ]
机构：
[1] Nippon Dent Univ, Grad Sch Life Dent Niigata, Field Oral & Maxillofacial Surg & Syst Med, Course Clin Sci,Oral & Maxillofacial Surg, Niigata, Japan
[2] Nippon Dent Univ, Sch Life Dent, Dept Oral & Maxillofacial Surg, Niigata, Japan
来源：
ANTICANCER RESEARCH | 2021年 / 41卷 / 07期
关键词：
Anticancer drug sensitivity test; CD-DST; paclitaxel; cetuximab; PTEN; VITRO CHEMOSENSITIVITY TEST; DROPLET-EMBEDDED CULTURE; GROWTH-FACTOR RECEPTOR; DRUG-SENSITIVITY TEST; HEAD; COMBINATION; RESISTANCE; RECURRENT; CANCER; CHEMOTHERAPY;
D O I：
10.21873/anticanres.15124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background/Aim: The mechanisms through which cetuximab (cMab) coadministration with paclitaxel (PTX) enhances antitumor efficacy remain unclear. We examined the mechanism of the antitumor enhancing effect of cMab by determining changes in gene expression in the PI3K-AKT pathway. Materials and Methods: Eight human oral squamous cell carcinoma (OSCC) cell lines were cultured three-dimensionally and exposed to PTX + cMab. The expression levels of PTEN mRNA in OSCC cell lines after anticancer drug treatment were assessed using real-time PCR. PTEN mRNA expression levels were also confirmed after administration of PTX + cMab in vivo. Western blot analysis was used to confirm the results at the protein level. Results: PTEN mRNA and protein expression were significantly increased only in the cell lines with high sensitivity to PTX + cMab, and similar results were observed in vivo. Conclusion: PTEN activation may enhance the antitumor effect of PTX + cMab.
引用
收藏
页码：3363 / 3370
页数：8
相关论文
共 28 条
  • [1] The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma
    da Costa, Alexandre A. B. A.
    Costa, Felipe D'Almeida
    Araujo, Daniel Vilarim
    Guedes Camandaroba, Marcos Pedro
    Fonseca de Jesus, Victor Hugo
    Oliveira, Audrey
    Fonseca Alves, Ana Caroline
    Stecca, Carlos
    Machado, Larissa
    Feraz de Oliveira, Andrea Cruz
    de Oliveira, Thiago Bueno
    Nicolau, Ulisses Ribaldo
    Cordeiro de Lima, Vladmir Claudio
    [J]. MEDICAL ONCOLOGY, 2019, 36 (01)
  • [2] Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab
    da Costa, Alexandre A. B. A.
    Costa, Felipe D'Almeida
    Ribeiro, Adriana R.
    Guimaraes, Andreia P.
    Chinen, Ludmila T.
    Lopes, Clovis A. P.
    de Lima, Vladmir C. C.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (02) : 282 - 289
  • [3] Epidermal growth factor receptor - targeted molecular therapeutics for head and neck squamous cell carcinoma
    Egloff, Ann Marie
    Grandis, Jennifer
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2006, 10 (05) : 639 - 647
  • [4] PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma
    Eze, Nnamdi
    Lee, Ju-Whei
    Yang, Dong-Hua
    Zhu, Fang
    Neumeister, Veronique
    Sandoval-Schaefer, Teresa
    Mehra, Ranee
    Ridge, John A.
    Forastiere, Arlene
    Chung, Christine H.
    Burtness, Barbara
    [J]. ORAL ONCOLOGY, 2019, 91 : 69 - 78
  • [5] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
    Ferris, R. L.
    Blumenschein, G., Jr.
    Fayette, J.
    Guigay, J.
    Colevas, A. D.
    Licitra, L.
    Harrington, K.
    Kasper, S.
    Vokes, E. E.
    Even, C.
    Worden, F.
    Saba, N. F.
    Iglesias Docampo, L. C.
    Haddad, R.
    Rordorf, T.
    Kiyota, N.
    Tahara, M.
    Monga, M.
    Lynch, M.
    Geese, W. J.
    Kopit, J.
    Shaw, J. W.
    Gillison, M. L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1856 - 1867
  • [6] Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx
    Fujii, Satoshi
    Uryu, Hideoki
    Akashi, Ken
    Suzuki, Kensuke
    Yamazaki, Manabu
    Tahara, Makoto
    Hayashi, Ryuichi
    Ochiai, Atsushi
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (03) : 454 - 463
  • [7] PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy
    Haddadi, Nahal
    Lin, Yiguang
    Travis, Glena
    Simpson, Ann M.
    McGowan, Eileen M.
    Nassif, Najah T.
    [J]. MOLECULAR CANCER, 2018, 17
  • [8] Hama T, 2021, JPN J CLIN ONCOL, V36, P436, DOI 10.5981/jjhnc.36.436
  • [9] Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-κB activity in human oral squamous cell carcinoma cell lines
    Harada, Koji
    Ferdous, Tarannum
    Kobayashi, Hiroaki
    Ueyama, Yoshiya
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (06) : 2439 - 2445
  • [10] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
    Hitt, R.
    Irigoyen, A.
    Cortes-Funes, H.
    Grau, J. J.
    Garcia-Saenz, J. A.
    Cruz-Hernandez, J. J.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (04) : 1016 - 1022
123